Biotech firms offer extraordinary growth potential thanks to their development of new drugs.
If a drug wins FDA approval, the company's stock has the chance to rocket higher.
That's why we're bringing you the best biotech stocks to buy in September 2018...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The numbers are staggering. Over the next six years, the biotech market is expected to add an additional $593 billion in value – a 419% increase over the size of today's biotech market.
Growth like this is why Wall Street is rushing hand over foot to buy the most lucrative biotech stocks available. With thousands of biotech stocks on the market, identifying the best biotech stocks to buy is incredibly difficult.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
By 2025, the biotech industry will be worth will be $727 billion – a 120% increase over its total value in 2015.
To help you take advantage of the tremendous gains in biotech stocks, we're bringing you the three best biotech stocks to buy this month.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Since hitting a high in late January, the iShares Nasdaq Biotechnology ETF has slumped more than 11%. But that doesn't mean investors should stop looking for the best biotech stocks to buy today.
You see, the slump in biotech stocks has little to do with their true worth.
In fact, some of the best biotech stocks are currently trading well below their fundamental value, according to their earnings and assets.
Here are the three best biotech stocks to buy now, while they're still on sale...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Biotech stocks have already netted investors huge gains.
In fact, we expect prices to skyrocket even further as the industry becomes a $727 billion juggernaut.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Biotech stocks have been getting hit hard in early 2018, but it's largely because of market overreactions to minor setbacks and rumors.
Based on earnings and assets, some biotech stocks are now available at remarkable discounts.
We've got three picks that are ready to break out in a big way.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Biotech stocks were among 2017's best performers, until news broke in October that congressional Republicans ditched efforts to repeal and replace Obamacare.
While the rest of the market was still soaring, the Wall Street herd simply turned its attention elsewhere – but that was a big mistake.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.
That's a correction, as defined by most market watchers.
And most investors – and their "enablers" on Wall Street – have shied away from biotech shares since. They're jittery.
In fact, I saw one august financial publication – the highly respected Investor's Business Daily – warn folks away from biotech in 2018 due to "median tenure of chief executives at large-cap biotech companies."
That's not just a stretch. It's a load of malarkey.
Here's the thing: If you want to double your money in 2018, you absolutely must invest in biotech.
That temporary dip in the iShares Nasdaq Biotechnology Index Fund ETF came after congressional Republicans ditched efforts to repeal and replace Obamacare. If there's one thing Wall Street hates, it's uncertainty.
As you might expect, Wall Street's panic led it to ignore some shares that have very bright futures – and are now trading at huge discounts.
So I've crunched the numbers – and done the research – and have identified three beaten-down biotech leaders that are poised to make huge comebacks throughout 2018.
I think you should put all three of these 2018 biotech comeback stocks on your "buy" list.
Especially the one that I believe will soar 110.5% in just 12 months...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Back in October, I did something crazy.
That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.
Here's why that move was a bit nuts.
At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.
Turns out, however, our crazy bet paid off.
Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.
That helped pushed biotech and drug stocks into a big uptrend.
And my paid-up members made peak gains of 116% – in just over eight months.
Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.
But to do that, you have to know how to find those deals.
I do.
Today I'll show you how you can, too.
And I'll reveal the three best biotech bargains out there right now.
All three have triple-digit gains potential...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Some of the most outrageous drug price increases of 2016 have placed huge burdens on patients and caregivers alike. According to an Oct. 11 report funded by the American Hospital Association (AHA), total net spending on prescription drugs by hospitals this year is up to $309.5 billion, making prescription drugs the fastest-growing segment of the […]
Here's our list of the most outrageous drug price increases of 2016...
Start the conversation